Study #2014-0514
A Phase 2 Study of pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and T-Cell non-Hodgkin Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab
Description
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), classical Hodgkin Lymphoma (cHL) or peripheral T-cell lymphoma (PTCL) in 1st remission.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
Study phase:
Phase II
Physician name:
Yago Nieto
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-893-4229
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.